Certara, Inc. (NASDAQ:CERT – Get Free Report) was the target of a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 4,330,000 shares, a drop of 18.1% from the August 31st total of 5,290,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is presently 4.2 days. Currently, 3.9% of the company’s stock are short sold.
Certara Trading Down 0.3 %
Shares of Certara stock traded down $0.04 on Monday, reaching $11.71. 2,007,275 shares of the company were exchanged, compared to its average volume of 733,681. Certara has a fifty-two week low of $10.35 and a fifty-two week high of $19.87. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of -30.03, a price-to-earnings-growth ratio of 5.17 and a beta of 1.49. The stock has a fifty day moving average price of $12.73 and a 200-day moving average price of $15.06.
Certara (NASDAQ:CERT – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $93.31 million for the quarter, compared to the consensus estimate of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The firm’s revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the company earned $0.10 earnings per share. On average, analysts expect that Certara will post 0.27 EPS for the current year.
Analysts Set New Price Targets
View Our Latest Report on CERT
Insider Buying and Selling
In related news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the transaction, the insider now owns 99,704 shares of the company’s stock, valued at $1,125,658.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.39% of the stock is currently owned by corporate insiders.
Institutional Trading of Certara
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Blue Trust Inc. bought a new position in shares of Certara during the 2nd quarter valued at approximately $26,000. Pineridge Advisors LLC purchased a new position in Certara during the fourth quarter valued at $28,000. Innealta Capital LLC bought a new stake in shares of Certara in the 2nd quarter worth about $36,000. YHB Investment Advisors Inc. purchased a new position in Certara during the 1st quarter valued at about $47,000. Finally, Intech Investment Management LLC purchased a new position in shares of Certara in the 2nd quarter worth approximately $152,000. Institutional investors own 73.96% of the company’s stock.
About Certara
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Further Reading
- Five stocks we like better than Certara
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Profitably Trade Stocks at 52-Week Highs
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- How to Invest in Small Cap Stocks
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.